News Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
News Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.
News Dizal breaks new ground for EGFR drugs in lung cancer Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
News Lilly's triple agonist retatrutide passes diabetes test Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.
News Generic semaglutide in India, and other weight-loss news Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
Patients Bringing awareness to Brain Tumour Month, personally This Brain Tumour Awareness Month, Inventus' Jim Michel reveals how living with a benign brain tumour has influenced his life.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.